Clear Cell Renal Cell Carcinoma Clinical Trial
— ENTRATAOfficial title:
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Verified date | August 2022 |
Source | Calithera Biosciences, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following: - At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) - Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1
Status | Completed |
Enrollment | 69 |
Est. completion date | June 1, 2020 |
Est. primary completion date | April 26, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Karnofsky Performance Score (KPS) = 70% - Estimated Life Expectancy of at least 3 months - Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component. - Measurable Disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the Investigator - Must have received at least two prior lines of systemic therapy, including at least one VEGF TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib) a) Radiographic progression of mRCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to Cycle 1 Day 1 (C1D1). - Prior treatment with other anti-cancer therapies including cytokines, monoclonal antibodies, immunotherapies, and cytotoxic chemotherapy is allowed Exclusion Criteria: - Prior treatment with mammalian target of rapamycin (mTOR) inhibitors (everolimus or temsirolimus) or CB-839 - Receipt of any anticancer therapy within the following windows before randomization: - TKI therapy within 2 weeks or 5 half-lives, whichever is longer - Any type of anti-cancer antibody within 4 weeks - Cytotoxic chemotherapy within 4 weeks - Investigational therapy within 4 weeks or 5 half-lives, whichever is longer - Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Patients with clinically relevant ongoing complications from prior radiation therapy are not eligible. - Unable to receive medications orally (PO) or any condition that may prevent adequate absorption of oral study medication - Major surgery within 28 days prior to randomization - Patients with active and/or untreated central nervous system (CNS) cancer are not eligible. Patients with treated brain metastasis must have 1) documented radiographic stability of at least 4 weeks duration demonstrated on baseline contrast-enhanced CNS imaging (eg contrast-enhanced magnetic resonance imaging [MRI] of the brain) prior to randomization and 2) must be symptomatically stable and off steroids for at least 2 weeks before randomization. - Requirement for continued proton pump inhibitor after randomization - Chronic treatment with corticosteroids or other immunosuppressive agents except (i) inhaled or topical steroids or replacement dose corticosteroids equivalent to = 10 mg prednisone and (ii) patients receiving physiological doses of hydrocortisone for adrenal insufficiency |
Country | Name | City | State |
---|---|---|---|
United States | Anne Arundel Medical Center Oncology and Hematology | Annapolis | Maryland |
United States | University Cancer & Blood Center, LLC | Athens | Georgia |
United States | University of Maryland, Greenebaum Comprehensive Cancer Center | Baltimore | Maryland |
United States | St. Vincent Frontier Cancer Center | Billings | Montana |
United States | St. Luke's Mountain States Tumor Institute | Boise | Idaho |
United States | Montefiore Medical Center | Bronx | New York |
United States | Charleston Hematology Oncology Associates,PA | Charleston | South Carolina |
United States | UT/Erlanger Oncology & Hematology | Chattanooga | Tennessee |
United States | Northwestern University | Chicago | Illinois |
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists | East Setauket | New York |
United States | Florida Cancer Specialists- South | Fort Myers | Florida |
United States | Parkview Research Center | Fort Wayne | Indiana |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | Mercy Clinic Oncology & Hematology | Joplin | Missouri |
United States | SCRI HCA Midwest | Kansas City | Missouri |
United States | Ann B. Barshinger Cancer Institute / Lancaster General Hospital | Lancaster | Pennsylvania |
United States | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada |
United States | Los Angeles Hematology Oncology Medical Group | Los Angeles | California |
United States | UCLA Department of Medicine - Hematology/Oncology | Los Angeles | California |
United States | Norton Cancer Institute, Norton Healthcare Pavilion | Louisville | Kentucky |
United States | University of Wisconsin Carbone Cancer Center | Madison | Wisconsin |
United States | Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia |
United States | NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology | Mineola | New York |
United States | Monongahela Valley Hospital | Monongahela | Pennsylvania |
United States | Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee |
United States | Ochsner Clinical Foundation | New Orleans | Louisiana |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Highlands Oncology Group | Rogers | Arkansas |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Metro-Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota |
United States | Florida Cancer Specialists- North | Saint Petersburg | Florida |
United States | Utah Cancer Specialists | Salt Lake City | Utah |
United States | Stanford Cancer Center | Stanford | California |
United States | SUNY Upstate Medical University | Syracuse | New York |
United States | The University of Arizona Cancer Center | Tucson | Arizona |
United States | Wenatchee Valley Hospital and Clinics | Wenatchee | Washington |
Lead Sponsor | Collaborator |
---|---|
Calithera Biosciences, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) | PFS was defined as the time from randomization to the date of documented disease progression (assessed by Investigator per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) within 2 scheduled scan intervals following previous evaluable radiologic tumor assessment or death for any cause, whichever occurred first. Participants with no documentation of disease progression or death on-study were censored at the date of last available tumor assessment.
Progressive Disease (PD) per RECIST 1.1: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. |
As of the primary data cutoff date of 26 Apr 2019; maximum duration of follow-up for PFS was 11.2 months. | |
Secondary | Overall Survival (OS) | Overall survival is defined as the time from randomization to the date of death from any cause. Participants with no documentation of death on-study were censored at the date at which they were last known to be alive. | As of the data cutoff date of 30 Sep 2020; maximum duration of follow-up for OS was 30.4 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT02307474 -
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
|
N/A | |
Completed |
NCT00101114 -
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Recruiting |
NCT05363631 -
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
|
Phase 1/Phase 2 | |
Terminated |
NCT01198158 -
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
|
Phase 3 | |
Completed |
NCT00378703 -
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
Recruiting |
NCT06088134 -
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
|
||
Recruiting |
NCT06049576 -
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
|
Phase 1 | |
Active, not recruiting |
NCT01038778 -
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05536141 -
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT01243359 -
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
|
Phase 1 | |
Terminated |
NCT00098618 -
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|
Phase 2 | |
Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06052852 -
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03680521 -
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT06195150 -
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
|
||
Active, not recruiting |
NCT02293980 -
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
|
Phase 1 |